SCHEMBL2947792

SCHEMBL2947792

CCOCCN(CCOCC)c1ccnc(NCCN)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.41
DNM2 P50570 2/20 0.36
CCR4 P51679 3/20 0.33
MET P08581 1/20 0.33
KDR P35968 1/20 0.33
SYK P43405 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
CDK1 P06493 1/20 0.32
UTS2R Q9UKP6 1/20 0.32
MKNK1 Q9BUB5 1/20 0.32
FERMT2 Q96AC1 2/20 0.32
HRH4 Q9H3N8 1/20 0.32
ALOX5AP P20292 1/20 0.32
FEN1 P39748 1/20 0.32
HTR7 P34969 1/20 0.31
PRKD3 O94806 1/20 0.31
EGFR P00533 1/20 0.31
PRKCG P05129 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2951032 0.87 CXCR4 (0.43) CXCR4DNM2KDRSYKHRH3
SCHEMBL2955015 0.83 DNM2 (0.46) CXCR4DNM2CCR4HRH3UTS2R
SCHEMBL2947401 0.79 CXCR4 (0.43) CXCR4DNM2SYKHRH3MKNK1
SCHEMBL2951597 0.79 DNM2 (0.45) CXCR4DNM2CCR4HRH3MKNK1
SCHEMBL1089789 0.78 DNM2 (0.42) CXCR4DNM2CCR4HRH3HRH4
SCHEMBL9932990 0.75 HRH3 (0.45) CXCR4DNM2KDRHRH3MKNK1
SCHEMBL1090836 0.75 CXCR4 (0.40) CXCR4DNM2CCR4HRH3MKNK1
SCHEMBL1091327 0.74 CXCR4 (0.43) CXCR4DNM2SYKHRH3FERMT2
SCHEMBL2955098 0.71 CHRM2 (0.54) CXCR4DNM2MKNK1
SCHEMBL13034199 0.68 CXCR4 (0.54) CXCR4SYKFERMT2ZAP70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885DNM2 4429/4885CCR4 22/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 CXCR4 1/4885DNM2 4429/4885CCR4 22/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885DNM2 4429/4885CCR4 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.